Stryker Corporation vs Unum Group Common Stock — how do they compare? Stryker Corporation trades at $285 (market cap $108.02B), while Unum Group Common Stock trades at $91.42 (market cap $14.48B). The key difference: Stryker Corporation is far larger — about 7.5× Unum Group Common Stock's market cap, and Unum Group Common Stock pays the higher dividend (2.21%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 22 Days and Unum Group Common Stock for 0 Days on average.
| SYK | UNM | |
|---|---|---|
Market Cap | $108.02B | $14.48B |
Volume | 2,222,698 | 2,214,044 |
Sector | Health | Financials |
52-Week High | $388.35 | $96.57 |
52-Week Low | $269.75 | $70.66 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $119.49B | $18.04B |
Dividend Yield | 1.25% | 2.21% |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →